Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Harvard Business School
Deloitte
Argus Health
Accenture
Cipla
Dow
Cerilliant
Merck
Citi

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,536,167

« Back to Dashboard

Which drugs does patent 8,536,167 protect, and when does it expire?

Patent 8,536,167 protects XTORO and is included in one NDA.

This patent has twenty patent family members in fourteen countries.
Summary for Patent: 8,536,167
Title:Methods for treating ophthalmic, otic, or nasal infections
Abstract: The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.
Inventor(s): Stroman; David W. (Irving, TX), Chowhan; Masood A. (Arlington, TX), Appell; Kenneth C. (Burleson, TX)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:12/829,973
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,536,167

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF ACUTE OTITIS EXTERNA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,536,167

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,119,859 Methods for treating otic infections ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,536,167

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 2012000136 ➤ Subscribe
South Korea 101541823 ➤ Subscribe
South Korea 20120114211 ➤ Subscribe
Japan 2015134827 ➤ Subscribe
Japan 5784012 ➤ Subscribe
European Patent Office 2448587 ➤ Subscribe
Japan 2012532115 ➤ Subscribe
China 105687111 ➤ Subscribe
China 102470139 ➤ Subscribe
Canada 2765852 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Fuji
Express Scripts
McKinsey
Novartis
US Army
AstraZeneca
Chubb
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot